A study of RET proto-oncogene polymorphisms in association with lung cancer risk in the Korean population.

نویسندگان

  • Hyun Kyung Kim
  • Hae-Yun Jung
  • Seungjoon Lim
  • Jae Sook Sung
  • Young Mi Whang
  • Ukhyun Jo
  • Jong Eun Lee
  • Sang Won Shin
  • Jun Suk Kim
  • Jeong Seon Ryu
  • Yeul Hong Kim
چکیده

BACKGROUND/AIM This study examined whether the polymorphisms at the promoter region of RET gene are associated with the risk of lung cancer in the Korean population. PATIENTS AND METHODS A total of 409 Korean lung cancer patients and 409 normal subjects were recruited. PCR-RFLP, SNaP Shot assay and logistic regression analyses were performed to characterize the association between polymorphisms of RET and lung cancer risk. RESULTS Four SNPs (-1697 C>G, -1260 C>T, -719 C>T, -527 C>A) of RET were selected for large-scale genotyping. Statistical analyses revealed that novel -1260 C > T polymorphism and haplotype 3 (-1697G, -1260T, -719C, and -719C) were associated with the risk of lung cancer; specifically, there were significant associations within subgroups of males and smokers. CONCLUSION These results demonstrated that this novel polymorphism of the RET gene is associated with an increased risk of lung cancer in the Korean population.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

جهش‌های ژرم لاین اگزون‌ 19 ژن پروتوآنکوژن RET در سرطان مدولاری تیرویید در یک نمونه جمعیت ایرانی

Background: Medullary thyroid cancer (MTC), includes 5-10% of all the thyroid cancers. RET proto-oncogene mutations have been found in association with MTC development. Therefore, identification of the mutations in RET can allow early diagnosis of the families who are at the risk of the disease. The goal of this study was to investigate existence and association between mutations in exon 19 of ...

متن کامل

RET proto-oncogene mutations in the diagnosis of medullary thyroid cancer: a review article

Medullary thyroid cancer accounts for 5-10% of thyroid carcinomas. RET proto-oncogene mutations occur in all of the hereditary MTCs and about 66% of the sporadic MTCs. So, the detection of the RET mutations is necessary for rapid and proper diagnosis and treatment. This systematic review seeks to find a comprehensive list of RET gene mutations in the diagnosis of medullary thyroid cancer. The ...

متن کامل

Point Mutations in RET Proto-Oncogene Exon 10 in Patients with Medullary Thyroid Carcinoma

Background & Aims: Thyroid cancer is the most common endocrine malignancy. Medullary thyroid carcinoma (MTC) is an aggressive malignant tumor arising from parafollicular cells of the thyroid. MTC occurs in hereditary (25%, hMTC) or sporadic (75%, sMTC) forms. The hMTC form has an autosomal dominant inheritance. RET proto-oncogene mutations, especially the 10, 11, and 16 exones, are associated w...

متن کامل

مقایسه سطح پلاسمایی هورمون کلسی‌تونین در افراد مبتلا به سرطان مدولاری تیرویید با و بدون جهش در اگزون 10 و 11 پروتوانکوژن RET

Background: Thyroid carcinoma is the most common endocrine malignancy and approximately accounts 2% of all cancer cases. Medullary thyroid cancer (MTC) is an endocrine tumor with differentiation of Parafollicular or C-cells and is categorized into hereditary or sporadic types. Medullary thyroid carcinoma approximately accounts for 5-10% of all thyroid carcinoma. Germ-line and somatic mutations ...

متن کامل

THE MUTATIONS OF RET PROTO-ONCOGENE IN MEDULLARY THYROID CARCINOMAS IN IRAN

MeduIIary thyroid carcinoma (MTC) occurs both sporadically and in the autosomal dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes. The distinction between true sporadic MTC and a new mutation familial case is important for future clinical management of both the patient and family. The susceptibility gene for hereditary MTC is the RET proto-oncogene. DNA analysis for g...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Anticancer research

دوره 30 9  شماره 

صفحات  -

تاریخ انتشار 2010